Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [41] CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Sila Cocciolillo
    Giustino Parruti
    Leonardo Marzio
    World Journal of Hepatology, 2014, (07) : 496 - 503
  • [42] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [43] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [44] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [45] The epidemiology of non-alcoholic fatty liver disease
    Bellentani, Stefano
    LIVER INTERNATIONAL, 2017, 37 : 81 - 84
  • [46] Non-alcoholic fatty liver disease in children
    Chaturvedi, Kanupriya
    Vohra, Pankaj
    INDIAN PEDIATRICS, 2012, 49 (09) : 757 - 758
  • [47] Pathology of non-alcoholic fatty liver disease
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2017, 37 : 85 - 89
  • [48] Non-alcoholic fatty liver disease and diabetes
    Reyes-Garcia, Rebeca
    Rozas-Moreno, Pedro
    Julio Llamoza-Torres, Camilo
    Mezquita-Raya, Pedro
    MEDICINA CLINICA, 2017, 148 (01): : 33 - 38
  • [49] Hyperuricemia in non-alcoholic fatty liver disease
    Dogru, T.
    Genc, H.
    Tapan, S.
    Bagci, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 1042 - 1043
  • [50] Mitochondria in non-alcoholic fatty liver disease
    Prip-Buus, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2016, 46 : 53 - 53